Astellas Pharma Gmbh

Kiyoshi Yahiro

Makoto Takeuchi

Takeshi Suzuki

Noriyuki Kawano

Hiroyuki Kaizawa

Hideki Kubota

Masanori Miura

Ryushi Seo

Issei Tsukamoto

Tomofumi Takuwa

Shinobu Mochizuki

Masahiro Iwata

Eiichi Nakai

Miki Kobayashi

Kazuhiro Nakatou

This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

2,4,6-Triamino-1,3,5-triazine derivative

The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. (wherein

Phenylpyridinecarbonylpiperazinederivative

Growing community of inventors

Tsukuba, Japan

Kiyoshi Yahiro